Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bayer Licenses Thrombosis Drug from Isis | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bayer Licenses Thrombosis Drug from Isis

Will assume clinical development and commercialization of ISIS-FXIRx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer HealthCare has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. for ISIS-FXIRx, an antisense investigational drug in development for the prevention of thrombosis. Bayer will further develop and commercialize ISIS-FXIRx in areas of high unmet medical need.
 
Isis is eligible to receive an upfront payment and payment for the advancement of the program following a Phase II study in patients with compromised kidney function. Isis is also eligible to receive milestone payments and royalties on sales. After completion of ongoing activities at Isis, Bayer will assume all global clinical development as well as worldwide regulatory and commercialization responsibilities for ISIS-FXIRx.
 
“Bayer is committed to developing therapies in areas of patient need and we share a common vision with Isis in developing ISIS-FXIRx,” said Dr. Joerg Moeller, member of the Bayer HealthCare Executive Committee and head of global development.
 
“We believe Bayer, a leading pharmaceutical company in the treatment of thrombotic disease, is the ideal partner for ISIS-FXIRx. Bayer has the expertise, commitment and resources to develop ISIS-FXIRx in areas where unmet medical needs exist. We are pleased with the value of this partnership, which supports a robust development program to maximize the value of ISIS-FXIRx globally and which allows us to participate significantly in future commercial success,” said Stanley Crooke, Ph.D, M.D., chief executive officer at Isis Pharmaceuticals.  
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics